Two AI health companies worth a combined $13 billion decided they work better together.
OpenEvidence, which handles more than 1 million clinical consultations daily across the U.S., announced a partnership with Tandem on April 2. The premise is simple: a doctor shouldn’t finish making a treatment decision and then hand off to an entirely separate administrative fight with the insurance company.
OpenEvidence provides real-time clinical guidance grounded in peer-reviewed research. Tandem automates what comes after: prescription generation, prior authorization submissions, appeals, pharmacy routing, and patient enrollment in financial assistance programs. The integration covers all drugs, all insurance plans, all pharmacies in the U.S.
The uncomfortable read for payers: if prior auth gets generated at the moment of the clinical decision, denial-on-process becomes a harder play. The appeal is already in the queue before the insurer has time to send a form letter.
Dr. Ania Bilski, VP of Clinical AI at OpenEvidence, put it plainly: “Clinicians shouldn’t have to choose between delivering care and navigating administrative complexity.”
OpenEvidence raised $250 million in a Series D in January, bringing total funding to nearly $700 million. Its valuation sits at $12 billion.